Published in final edited form as:

Pharmacol Biochem Behav. 2011 September ; 99(3): 428–436. doi:10.1016/j.pbb.2011.03.002.

Ethanol-Induced Changes in the Expression of Proteins Related to Neurotransmission and Metabolism in Different Regions of the Rat Brain

Natalie M. Zahr, Ph.D.^{a,b}, Richard L. Bell, Ph.D.^c, Heather N. Ringham, M.S.^d, Edith V. Sullivan, Ph.D.^a, Frank A. Witzmann, Ph.D.^d, and Adolf Pfefferbaum, M.D.^{a,b}

^a Psychiatry & Behavioral Sciences, Stanford University School of Medicine, 401 Quarry Rd., Stanford, CA 94305, USA

^b Neuroscience Program, SRI International, 333 Ravenswood Rd., Menlo Park, CA, USA

^c Department of Psychiatry and Behavioral Sciences, Indiana University School of Medicine, Institute of Psychiatric Research, 791 Union Drive, Indianapolis, IN 46202, USA

^d Department of Cellular & Integrative Physiology, Indiana University School of Medicine, Biotechnology Research & Training Center, 1345 West 16th Street, Room 308, Indianapolis, IN 46202, USA

Abstract

Despite extensive description of the damaging effects of chronic alcohol exposure on brain structure, mechanistic explanations for the observed changes are just emerging. To investigate regional brain changes in protein expression levels following chronic ethanol treatment, one rat per sibling pair of male Wistar rats was exposed to intermittent (14 hr/day) vaporized ethanol, the other to air for 26 weeks. At the end of 24 weeks of vapor exposure, the ethanol group had blood ethanol levels averaging 450 mg %, had not experienced a protracted (>16 hr) withdrawal from ethanol, and revealed only mild evidence of hepatic steatosis. Extracted brains were micro-dissected to isolate the prefrontal cortex (PFC), dorsal striatum (STR), corpus callosum genu (CCg), CC body (CCb), anterior vermis (AV), and anterior dorsal lateral cerebellum (ADLC) for protein analysis with two-dimensional gel electrophoresis. Expression levels for 54 protein spots were significantly different between the ethanol- and air- treated groups. Of these 54 proteins, tandem mass spectroscopy successfully identified 39 unique proteins, the levels of which were modified by ethanol treatment: 13 in the PFC, 7 in the STR, 2 in the CCg, 7 in the CCb, 7 in the AV, and 5 in the ADLC. The functions of the proteins altered by chronic ethanol exposure were predominately associated with neurotransmitter systems in the PFC and cell metabolism in the STR. Stress response proteins were elevated only in the PFC, AV, and ADLC perhaps supporting a role for frontocerebellar circuitry disruption in alcoholism. Of the remaining proteins, some had functions associated with cytoskeletal physiology (e.g., in the CCb) and others with transcription/translation (e.g., in the ADLC). Considered collectively, all but 4 of the 39 proteins identified in the present study have been previously identified in ethanol gene- and/or protein- expression studies lending support for their role in ethanol-related brain alterations.

© 2011 Elsevier Inc. All rights reserved.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Keywords

Vapor Chambers; Proteomics; Frontocerebellar Circuitry

INTRODUCTION

Decades of postmortem and in vivo study have provided an extensive description of the untoward effects of chronic alcoholic exposure on brain morphology (cf., Chanraud et al., 2010; Pfefferbaum et al., 2004; Sullivan et al., 2010), neurochemistry (e.g., Durazzo et al., 2010), cellular structure (e.g., Pentney and Dlugos, 2000), and metabolism (e.g., Volkow et al., 1990) even in the absence of common concomitants of alcohol abuse such as thiamine deficiency (Butterworth, 1995) or liver disease (Anand, 1999). The mechanisms of disruption, however, are still not well understood. High-throughput assays, such as proteomics, are particularly useful in the investigation of complex, multi-factorial diseases like alcoholism, and provide a new avenue of exploration regarding the means whereby alcohol impairs the brain. Animal models, by providing control over the pattern of ethanol exposure, including age at initial exposure, dosage, and number of withdrawals, allow for specific inquiry uncompromised by variables that can rarely be controlled in the heterogeneous population of human alcoholics.

Ethanol-vapor exposure of rats is a method that results in rapid induction of dependence (Roberts et al., 2000). In the present study, the longitudinal effects of vaporized ethanol exposure were investigated in sibling pairs of wild-type Wistar rats, with one rat per pair exposed to escalating doses of vaporized ethanol, the other to vapor chamber air. In vivo magnetic resonance imaging (MRI) was used to evaluate brain structure and MR spectroscopy (MRS) to evaluate brain biochemistry before and twice during ethanol exposure. After 16 weeks, blood alcohol levels (BALs) approximated 300 mg% and after an additional 8 weeks (i.e., after 24 weeks), BALs approached 450 mg%. MRI revealed a profile of significant ventricular expansion after ethanol vapor exposure: ventricular volume expanded by 8% in the controls, but by nearly 30% in the ethanol-exposed rats between baseline and week 24 (Pfefferbaum et al., 2008). Although enlargement of the lateral ventricles is assumed to result from atrophy of surrounding brain tissue, recent findings suggest that rather than overt cell loss, ventricular expansion likely reflects shrinkage of brain cells (including neurons, astrocytes, oligodendrocytes, microglia) and their processes (Zahr et al., 2010b). MRS in a 0.25 cm³ voxel containing the striatum revealed a significantly higher MRS-detectable signal from choline-containing compounds (Cho) at weeks 16 and 24 (Zahr et al., 2009). Higher levels of Cho can have various interpretations, including but not limited to inflammation, demyelination (Mader et al., 2008), impaired energy utilization (Djuricic et al., 1991), or cell membrane disruption (Griffin et al., 2001). Higher glutamine (Gln) was detected at week 16 (but not week 24), and higher glutamate (Glu) was observed at week 24 in the ethanol compared with the control group (Zahr et al., 2010a) indicating a disruption in Glu homeostasis.

To approach a mechanistic explanation for the changes observed in vivo, brains from these rats exposed to a total of 26 weeks of vaporized ethanol and their controls that had already undergone MR analysis were harvested and submitted to proteomic investigation. Several regions were selected because of their variable involvement in or susceptibility to ethanol-induced brain alterations (Harper, 2009). The basal ganglia, a key structure of which is the dorsal striatum (STR), was chosen because of its putative involvement in the loss of control over alcohol consumption (Tabakoff, 1979). The other brain regions were chosen either because of their known susceptibility to nutritional (i.e., thiamine) deficiencies (e.g., prefrontal cortex {PFC}, corpus callosum genu {CCg}, anterior vermis {AV}, and anterior

dorsal lateral cerebellum {ADLC}) or because of their vulnerability to alcohol-related liver disease (e.g., AV and body of the corpus callosum body {CCb})(Matsumoto, 2009).

METHODS

Study Group

The initial study group comprised 10 sibling pairs of healthy male heterogeneous stock Wistar rats (Charles River Laboratories) that were singly housed with free access to food and water and acclimated to a reversed 14 hr light/10 hr dark cycle (i.e., lights on at 1900 to 0900 hr for the rats' sleep cycle). The Institutional Animal Care and Use Committees at SRI International and Stanford University approved all procedures. This group of rats also underwent brain structural (with MRI Pfefferbaum et al., 2008) and biochemical (with MRS Zahr et al., 2009) examination.

Ethanol Exposure

One rat from each sibling pair was exposed to a compressed mixture of ethanol and room air (ethanol group weight at start of experiment: 625.88 ± 97.41 g) and the other to room air alone (control group weight: 629 ± 76.88 g) using a rodent ethanol inhalation system (La Jolla Alcohol Research Inc., La Jolla, CA) for a total of 26 weeks. In the first 16 weeks of ethanol exposure, 2 rats in the ethanol group died; an additional rat from the ethanol group died after the last MR examination before his brain could be properly harvested for proteomic analysis. Ethanol vapor was created by dripping 95% ethanol into a 4 L Erlenmeyer vacuum flask kept at 50°C on a warming tray. Air was blown across the flask at 11 L/min to vaporize the ethanol. Concentrations of ethanol vapor were adjusted by varying the rate at which ethanol was pumped into the flask and ranged from 15 to 30 mg/L. Chambers administering intermittent vapor were connected to a timer that would turn the pumps on and off every day so that animals received ethanol vapor for 14 hr at night during their sleep cycle (i.e., starting at 1900 hr). Ethanol vapor exposure is a reliable technique allowing animals to move about freely and permitting maintenance of high and specific BALs (Roberts et al., 2000). Tail blood (~0.5 ml) sampled for BAL determination was collected into heparinized Eppendorf tubes. After centrifugation, the plasma was extracted and assayed for ethanol content based on direct reaction with the enzyme ethanol oxidase (Analox Instruments Ltd., London, UK). After 24 weeks of ethanol exposure, BALs in the ethanol group reached an average of 450 mg %. Rats did not experience protracted (>16 hr) withdrawal at any time.

Neurological Examination

To characterize behavior following prolonged (i.e., 24 weeks) ethanol exposure, each rat was evaluated with examination of 33 neurological signs (extracted from Becker, 2000; Pitkin and Savage, 2001) 1 hr and 9 hr after the pumps were turned off: two time points were chosen to test for potential differences in behavior between immediate exposure to and acute withdrawal from ethanol. After 24 weeks of exposure, BALs approached ~450 mg %, and the final MRI and MRS data were acquired. On the day prior to MR examination, within 1 hr of ethanol exposure, all 8 alcoholized rats demonstrated neurological signs including lacrimation, nasal discharge, exophthalmoses, agitation, aggressiveness, and impairment of righting reflex. At 9 hr after ethanol exposure, all 8 alcoholized rats continued to demonstrate altered autonomic and motor functions, and 4 of the 8 exhibited tremor (Zahr et al., 2009). The presence of tremor likely indicates acute withdrawal (Becker, 2000). Following the final MRI and MRS, all animals were placed back in their vapor chambers for 2 weeks until euthanasia.

Sample Preparation and Protein Separation

After 26 weeks of ethanol exposure, within 3 hr of being removed from their vapor chambers, animals were euthanized and their brains were extracted, flash-frozen, and stored at -80°C . Subsequently, the PFC, STR, CCg, CCB, AV, and ADLC were micropunched for two-dimensional gel electrophoresis (2-DE, Figure 1). For 2-DE, samples included appropriately preserved tissue from 6 ethanol-exposed animals and 7 control animals. Each brain tissue region consisted of 10 micropunched tissue samples except for the CCB, which consisted of 28 micropunched tissue samples. The samples were solubilized in 550 μL (1.1 mL for CCB) of a solubilization buffer containing 9 M urea, 4% CHAPS, 1% dithiothreitol (DTT), and 1% carrier ampholytes (pH 3–10). Samples were vortexed every 15 min for 1 hr and incubated at 37°C between vortex sessions. While it is well known that urea + heat + protein = carbamylation due to the formation of isocyanic acid and its reaction with the N-terminus, arginine, lysine, and cysteine residues of proteins, we have consistently shown that the brief incubation at 37°C in the urea-based lysis buffers described above has no artifactual carbamylation effect on protein charge modification (Witzmann, 2005). After vortexing, each sample was sonicated using 3×2 sec bursts at setting 3 with a Fisher Sonic Dismembrator every 15 min for 1 hr and incubated at 37°C between sonications. Protein concentration was determined using the 2-D Quant Kit (GE Healthcare, Pittsburgh, PA), an approach that enables the sensitive and accurate assay of solubilized proteins to be performed without interference from constituents of the lysis buffer.

Two-Dimensional Gel Electrophoresis and Image Analysis

Using overnight, passive rehydration at room temperature, 200 μg of protein was loaded onto IPG strips (24 cm, nonlinear pH 3–10, BioRad, Hercules, CA). Isoelectric focusing (IEF) was performed simultaneously on all IPG strips randomly assigned to two Protean IEF Cells (BioRad, 10 strips/instrument) by a program of progressively increasing voltage (150 V for 2 hr, 300 V for 4 hr, 1500 V for 1 hr, 5000 V for 5 hr, 7000 V for 6 hr, and 10,000 V for 3 hr) for a total of 100,000 V hr.

First-dimension IPG strips were loaded directly onto second-dimension sodium dodecyl sulfate (SDS) slab gels (20 $\times$ 25 $\times$ 0.15 cm) with a 10–20% acrylamide gradient (Jule, Inc.) following equilibration for 10 min in Equilibration Buffer I (6 M urea, 2% SDS, 0.375 M Tris-HCl pH 8.8, 20% glycerol, 130 mM DTT) and 10 min in Equilibration Buffer II (6 M urea, 2% SDS, 0.375 M Tris-HCl pH 8.8, 20% glycerol, 135 mM iodoacetamide). All 13 second-dimension slab gels (7 control samples, 6 ethanol-treated samples {1 gel/sample} for each of the 6 regions equals a total of 78 gels) were run in parallel at 8°C for 20 hr at 160 V and subsequently fixed and stained using a modified colloidal Coomassie Blue G-250 procedure with 1 ng protein/spot sensitivity (Candiano et al., 2004). After 96 hr, gels were washed several times with water and scanned at 95.3- μm /pixel resolution using an ImageScanner III (GE Healthcare, Pittsburgh, PA).

The resulting 12-bit images were analyzed using Progenesis SameSpotsTM (v3.0, Nonlinear Dynamics, Durham, NC) and its embedded ANOVA analytic software. Alpha was set at $p \leq 0.015$ for all analyses. Six separate analyses were performed for each of the brain regions. Each analysis consisted of a one-way ANOVA comparing control vs. ethanol treated samples. Background was subtracted and protein spot density peaks detected and counted. Because total spot counts and the total optical density are directly related to the total protein concentration (Maldve et al., 2002), individual protein quantities were expressed as parts per-million (ppm) of the total integrated optical density after normalization against total image density. A reference pattern was selected and each of the gel images in the match-set was matched to the reference pattern using the software's advanced automated image alignment. Raw quantitative data for each protein spot were then analyzed statistically.

Mass Spectrometry

Protein spots of interest were manually excised from the gels. The protein spots were destained, reduced with DTT, alkylated with iodoacetamide, and tryptically digested using sequence grade, modified trypsin (Princeton Separations, Freehold, NJ). Resulting peptides were extracted from the gel plugs through a series of buffer exchanges, including 0.1% FA in 30% ACN, 0.1% FA in 50% ACN, and 100% ACN. Subsequently, peptides were concentrated and purified via speed vacuum centrifugation followed by a ZipTip® (Millipore, Billerica, MA) protocol.

Peptide samples (40 µL) were injected into a Thermo Scientific (Waltham, MA) LTQ linear ion trap mass spectrometer using a Michrom Paradigm AS1 auto-sampler coupled to a Paradigm MS4 High Performance Liquid Chromatography (HPLC) column (Michrom BioResources, Inc., Auburn, CA). The peptide solution was automatically loaded at a flow rate of 0.5 µL/min across a Paradigm Platinum Peptide Nanotrap (Michrom BioResources, Inc.) and onto a 150 × 0.099 mm capillary column (Polymicro Technologies, L.L.C., Phoenix, AZ) packed in-house using a 5 µm, 100 Å pore size Magic C18 AQ stationary phase (Michrom BioResources, Inc.). Mobile phases A (2% acetonitrile in 0.1% formic acid), B (98% acetonitrile in 0.1% formic acid), and C (5% acetonitrile in 0.1% formic acid) were all made in HPLC grade water. Buffer C was used to load the sample, and the gradient elution profile was as follows: 5% B (95% A) for 10 min; 5–55% B (95–45% A) for 30 min; 55–80% B (45–20% A) for 5 min; and 80–5% B (20–95% A) for 10 min. The data were collected in a “Triple-Play” (MS scan, Zoom scan, and MS/MS scan) mode using nanospray ionization with normalized collision energy of 35%.

The acquired mass spectral data were searched against the International Protein Index rat database (ipi.RAT.v337) using the SEQUEST (v. 28, rev. 12) program in Bioworks (v. 3.3, Thermo Scientific)(Curtin et al., 2009). General parameters were set as follows: peptide tolerance 2.0 atomic mass units (AMU), fragment ion tolerance 1.0 AMU, enzyme limits set as “fully enzymatic – cleaves at both ends” and missed cleavage sites set at 2. The searched peptides and proteins were subjected to the validation processes PeptideProphet (Keller et al., 2002) and ProteinProphet (Nesvizhskii and Aebersold, 2004) in the Trans-Proteomic Pipeline (v. 3.3.0) (<http://tools.proteomecenter.org/software.php>), and only those proteins with greater than 90% confidence were considered positive identifications. Protein functions were derived from either the EntrezGene or UniProtKB/Swiss-Prot entries provided at GeneCards® (www.genecards.org).

RESULTS

Approximately 2,000 proteins were resolved, matched, and analyzed in 2-D gel patterns of the various brain regions studied. The expression levels of 54 protein spots were significantly different between the ethanol (n=6) and air (n=7) treated groups. Of the 54, tandem mass spectroscopy successfully identified 39 differentially expressed unique proteins and 2 post-translationally modified proteins (Tables 1 & 2). Of 17 spots in the PFC, 13 were identified (6 down-regulated); 7 of 8 spots were identified in the STR (6 down-regulated), 2 of 5 spots were identified in the CCg (both down-regulated), 7 of 7 spots were identified in the CCb (6 down-regulated, 1 *isoform*), 7 of 9 spots were identified in the AV (3 down-regulated, 1 *isoform*), and 5 of 8 spots were identified in the ADLC (2 down-regulated). One of the proteins identified in the CCb (i.e., TUBA1 A) and one in the AV (i.e., SNAP25) appeared in 2 separate spots suggesting post-translational-modification of the same protein. Comparison of the identified proteins in various brain region images by homologous position suggests that the majority of these proteins were present in all regions analyzed, but the statistically significant differences in expression levels were unique to the regions mentioned.

DISCUSSION

Proteomic analysis using 2-DE and tandem mass spectrometry identified 39 unique proteins in 6 different brain regions, the levels of which were significantly modified by 26 weeks of vaporized ethanol exposure. The proteins changed with chronic ethanol exposure were selective to each brain region examined and could be distinguished by function (Table 3). Regional grouping by function highlights brain circuits relevant to alcohol use disorders. In particular, the levels of stress response proteins (i.e., Gsto, Hspd1, Hspa5, and Prdx5) were elevated only in the PFC and both regions of the cerebellum sampled (i.e., AV and ADLC), but in none of the other regions examined. This selective finding may support the hypothesized role of dysfunctional frontocerebellar circuitry in contributing to characteristic behaviors of alcoholics (e.g., Sullivan et al., 2003; Zahr et al., 2010c). This concept is further supported by the finding that the PFC and the cerebellum may be particularly responsive to ethanol as evidenced by the higher number of proteins identified in these regions (13 in the PFC and 12 in the combined cerebellar regions) compared to the others.

The PFC also revealed nearly all of the neurotransmitter-related protein changes observed, including those related to both glutamate and dopamine signaling (i.e., Syn2, Gnb2l1, Vdac2, Qdpr). This finding emphasizes the sensitivity of the PFC to alterations in neurotransmitter function and the potential neuroadaptations that occur in the PFC during addiction (Koob and Volkow, 2010). Indeed, the shift to habitual behavior (i.e., addiction) seems to depend, in part, on glutamatergic projections from the PFC to the ventral striatum (Kalivas and O'Brien, 2008).

Four of the nine proteins identified in the combined corpus callosal regions had metabolic functions. Both pathological (Harper and Kril, 1988; Tarnowska-Dziduszko et al., 1995) and structural MRI (Estruch et al., 1997; Pfefferbaum et al., 1996) studies demonstrate that the area of corpus callosum is reduced and its microstructure compromised (Pfefferbaum et al., 2006; Pfefferbaum et al., 2009) in alcoholics. A metabolic compromise may explain the reduction of the corpus callosum area often seen in alcoholics.

All but one of the seven proteins changed in the STR had functions related to metabolism. Altogether, 16 of the 41 proteins identified in this study had functions related to metabolism including the regulation of fundamental cellular processes (e.g., Stmn1, Uchl1) and the normal production of ATP (e.g., Adk, Cox6a1, Ldhd, Pkm2). The general decrease in the levels of these proteins might indicate a compromise to the normal functioning of brain cells. Indeed, these in vitro results may provide a potential mechanistic explanation for the in vivo MRI finding of ventricular enlargement (Pfefferbaum et al., 2008). If brain cells are metabolically compromised, an adaptive response may be the decrease or deletion of their dendritic arbor (e.g., Sullivan et al., 2003) resulting in the appearance of brain volume shrinkage (Zahr et al., 2010b).

Such protein changes may also provide an explanation for the increase in brain Cho observed using MRS following the 16 and 24 weeks of ethanol exposure. Potential interpretations for higher levels of Cho include cell membrane disruption (Griffin et al., 2001) or demyelination (Mader et al., 2008). At least 7 (i.e., Acta1, Actb, Cacybp, Mylc2b, Nefl, Tpm2, and Tuba1a) of the 39 uniquely identified proteins in this study are cytoskeletal. Adaptive changes to the structure of brain cells such as retraction of their dendritic arbor (i.e., cell membrane disruption) or demyelination (cf., He et al., 2007; Mayfield et al., 2002; Pfefferbaum et al., 2009) could result in an altered cytoskeleton and release of Cho-containing compounds (Zeisel, 1993).

Over 500 proteins have been identified as altered by ethanol in brain tissue collected from humans and rodents: frontal cortex (Alexander-Kaufman et al., 2007a; Alexander-Kaufman

et al., 2006; Etheridge et al., 2009; Lewohl et al., 2004), occipital cortex (Etheridge et al., 2009), hippocampus (Hargreaves et al., 2009; Matsuda-Matsumoto et al., 2007), corpus callosum (Kashem et al., 2008; Kashem et al., 2007), nucleus accumbens (Bell et al., 2006; McBride et al., 2009; Witzmann et al., 2003), amygdala (Bell et al., 2006), and cerebellar vermis (Alexander-Kaufman et al., 2007b). Accordingly, as presented in Table 4, the majority of the proteins detected in the current study have previously been identified as altered by ethanol exposure in human and rodent, genomic or proteomic studies. In human studies, it is difficult to control for and report the number, frequency, or length of abstinence attempts or withdrawals. With respect to rodent experiments, one of the previous ethanol-related proteomics studies describes the results of either multiple scheduled access or continuous free-choice access to ethanol with brains harvested within 12 hr of the last ethanol exposure (Bell et al., 2006). In another two of the ethanol-related proteomics studies in rats referenced herein (e.g., Masuo et al., 2009; McBride et al., 2009), 24 hr of abstinence preceded euthanasia, and in a final study, 2 weeks of an alcohol-free “washout period” preceded tissue extraction (Hargreaves et al., 2009). Thus, in all but one of the rodent proteomics studies previously conducted in which ethanol exposure was manipulated, the findings are primarily due to the consequences of ethanol exposure and not of protracted withdrawal (i.e., the ethanol withdrawal period did not exceed 24 hr).

Of the 39 unique proteins identified in the current study, only 4 have not been previously reported as altered by ethanol: Adk, Hibch, Itpa, and Phox2a. Despite their absence in the literature regarding gene or protein responsivity to ethanol, both Adk and Hibch may be associated with alcohol use disorders. Adenosine kinase (i.e., Adk) regulates the concentration of adenosine, an endogenous purine nucleoside that modulates many physiological processes. Ethanol inhibits adenosine reuptake and increases extracellular adenosine (Mailliard and Diamond, 2004). Similarly, in cirrhosis of the liver, a common complication of chronic alcoholism (Mann et al., 2003), Hibch activity in the liver is low (Ishigure et al., 2001; Taniguchi et al., 1996). To our knowledge, this is the first documentation of alterations in Itpa or Phox2a following ethanol exposure.

Although the false discovery rates (FDR, Q-values and associated p-values, Table 1) obtained herein suggest modest to high false positive levels, the fact that the majority of proteins identified in this study have been reported from both preclinical and post-mortem clinical studies supports replication of previous findings. While the observed replications with previous findings provide confidence in the results, the fact that different methodologies were used indicates caution is warranted when interpreting the present findings. To provide even greater support for similar findings in the future, especially when modest to high FDR are present, protein expression differences can be validated immunologically using Western blot analyses. Alternatively, if suitable antibodies are not available, validation can be done using mass spec-based selected reaction monitoring (SRM).

CONCLUSIONS

Brains of heterogeneous stock Wistar rats exposed to 26 weeks of vaporized ethanol differed from non-exposed controls in the expression levels of 41 proteins involved in selective cellular processes. Processes implicated include neurotransmission, metabolism, cytoskeletal physiology, stress responses, and transcription/translation. Based on the high number of responsive genes in the PFC and cerebellum and the commonality of their functions, the findings here may support the hypothesized role of frontocerebellar dysfunction in alcoholism. In addition, the high number of metabolic proteins with ethanol-associated altered expression levels may provide a potential mechanism for the ventricular expansion and callosal shrinkage commonly observed in chronic alcoholics.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The National Institute on Alcohol Abuse and Alcoholism provided support for this research with grants to AP (AA005965, AA013521-INIA), EVS (AA017168), and RLB (AA013522-INIA).

References

- Alexander-Kaufman K, Dedova I, Harper C, Matsumoto I. Proteome analysis of the dorsolateral prefrontal region from healthy individuals. *Neurochem Intl*. 2007a; 51:433–439.
- Alexander-Kaufman K, Harper C, Wilce P, Matsumoto I. Cerebellar vermis proteome of chronic alcoholic individuals. *Alcohol Clinical Exp Res*. 2007b; 31:1286–1296. [PubMed: 17561921]
- Alexander-Kaufman K, James G, Sheedy D, Harper C, Matsumoto I. Differential protein expression in the prefrontal white matter of human alcoholics: a proteomics study. *Mol Psychiatry*. 2006; 11:56–65. [PubMed: 16172612]
- Anand BS. Cirrhosis of liver. *The West J Med*. 1999; 171:110–115.
- Becker HC. Animal models of alcohol withdrawal. *Alcohol Res Health*. 2000; 24:105–113. [PubMed: 11199277]
- Bell RL, Kimpel MW, Rodd ZA, Strother WN, Bai F, Peper CL, Mayfield RD, Lumeng L, Crabb DW, McBride WJ, Witzmann FA. Protein expression changes in the nucleus accumbens and amygdala of inbred alcohol-preferring rats given either continuous or scheduled access to ethanol. *Alcohol*. 2006; 40:3–17. [PubMed: 17157716]
- Butterworth RF. Pathophysiology of alcoholic brain damage: synergistic effects of ethanol, thiamine deficiency and alcoholic liver disease. *Metab Brain Dis*. 1995; 10:1–8. [PubMed: 7596324]
- Candiano G, Bruschi M, Musante L, Santucci L, Ghiggeri GM, Carnemolla B, Orecchia P, Zardi L, Righetti PG. Blue silver: a very sensitive colloidal Coomassie G-250 staining for proteome analysis. *Electrophoresis*. 2004; 25:1327–1333. [PubMed: 15174055]
- Chanraud, S.; Pitel, AL.; Sullivan, EV. Structural imaging of alcohol abuse. In: Shenton, ME.; Turetsky, BI., editors. *Understanding Neuropsychiatric Disorders*. Cambridge University Press; 2010.
- Curtin LI, Grakowsky JA, Suarez M, Thompson AC, DiPirro JM, Martin LB, Kristal MB. Evaluation of buprenorphine in a postoperative pain model in rats. *Comp Medicine*. 2009; 59:60–71.
- Djuricic B, Olson SR, Assaf HM, Whittingham TS, Lust WD, Drewes LR. Formation of free choline in brain tissue during in vitro energy deprivation. *J Cereb Blood Flow Metab*. 1991; 11:308–313. [PubMed: 1997502]
- Durazzo TC, Pathak V, Gazdzinski S, Mon A, Meyerhoff DJ. Metabolite levels in the brain reward pathway discriminate those who remain abstinent from those who resume hazardous alcohol consumption after treatment for alcohol dependence. *J Stud Alcohol Drugs*. 2010; 71:278–289. [PubMed: 20230726]
- Estruch R, Nicolas JM, Salamero M, Aragon C, Sacanella E, Fernandez-Sola J, Urbano-Marquez A. Atrophy of the corpus callosum in chronic alcoholism. *J Neurol Sci*. 1997; 146:145–151. [PubMed: 9077511]
- Etheridge N, Lewohl JM, Mayfield RD, Harris RA, Dodd PR. Synaptic proteome changes in the superior frontal gyrus and occipital cortex of the alcoholic brain. *Proteomics Clin Appl*. 2009; 3:730–742. [PubMed: 19924264]
- Griffin JL, Mann CJ, Scott J, Shoulders CC, Nicholson JK. Choline containing metabolites during cell transfection: an insight into magnetic resonance spectroscopy detectable changes. *FEBS Letters*. 2001; 509:263–266. [PubMed: 11741600]
- Hargreaves GA, Quinn H, Kashem MA, Matsumoto I, McGregor IS. Proteomic analysis demonstrates adolescent vulnerability to lasting hippocampal changes following chronic alcohol consumption. *Alcohol Clinical Exp Res*. 2009; 33:86–94. [PubMed: 18945221]

- Harper C. The neuropathology of alcohol-related brain damage. *Alcohol Alcohol*. 2009; 44:136–140. [PubMed: 19147798]
- Harper CG, Kril JJ. Corpus callosal thickness in alcoholics. *Br J Addict*. 1988; 83:577–580. [PubMed: 3382816]
- He X, Sullivan EV, Stankovic RK, Harper CG, Pfefferbaum A. Interaction of thiamine deficiency and voluntary alcohol consumption disrupts rat corpus callosum ultrastructure. *Neuropsychopharmacology*. 2007; 32:2207–2216. [PubMed: 17299515]
- Ishigure K, Shimomura Y, Murakami T, Kaneko T, Takeda S, Inoue S, Nomoto S, Koshikawa K, Nonami T, Nakao A. Human liver disease decreases methacrylyl-CoA hydratase and beta-hydroxyisobutyryl-CoA hydrolase activities in valine catabolism. *Clin Chim Acta*. 2001; 312:115–121. [PubMed: 11580916]
- Kalivas PW, O'Brien C. Drug addiction as a pathology of staged neuroplasticity. *Neuropsychopharmacology*. 2008; 33:166–180. [PubMed: 17805308]
- Kashem MA, Harper C, Matsumoto I. Differential protein expression in the corpus callosum (genu) of human alcoholics. *Neurochem Intl*. 2008; 53:1–11.
- Kashem MA, James G, Harper C, Wilce P, Matsumoto I. Differential protein expression in the corpus callosum (splenium) of human alcoholics: a proteomics study. *Neurochem Intl*. 2007; 50:450–459.
- Keller A, Nesvizhskii AI, Kolker E, Aebersold R. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. *Anal Chem*. 2002; 74:5383–5392. [PubMed: 12403597]
- Koob GF, Volkow ND. Neurocircuitry of addiction. *Neuropsychopharmacology*. 2010; 35:217–238. [PubMed: 19710631]
- Lewohl JM, Van Dyk DD, Craft GE, Innes DJ, Mayfield RD, Cobon G, Harris RA, Dodd PR. The application of proteomics to the human alcoholic brain. *Ann N Y Acad Sci*. 2004; 1025:14–26. [PubMed: 15542695]
- Mader I, Rauer S, Gall P, Klose U. (1)H MR spectroscopy of inflammation, infection and ischemia of the brain. *Euro J Rad*. 2008; 67:250–257.
- Mailliard WS, Diamond I. Recent advances in the neurobiology of alcoholism: the role of adenosine. *Pharmacol Ther*. 2004; 101:39–46. [PubMed: 14729391]
- Maldve RE, Zhang TA, Ferrani-Kile K, Schreiber SS, Lippmann MJ, Snyder GL, Fienberg AA, Leslie SW, Gonzales RA, Morrisett RA. DARPP-32 and regulation of the ethanol sensitivity of NMDA receptors in the nucleus accumbens. *Nat Neuro*. 2002; 5:641–648.
- Mann RE, Smart RG, Govoni R. The epidemiology of alcoholic liver disease. *Alcohol Res Health*. 2003; 27:209–219. [PubMed: 15535449]
- Masuo Y, Imai T, Shibato J, Hirano M, Jones OA, Maguire ML, Satoh K, Kikuchi S, Rakwal R. Omic analyses unravels global molecular changes in the brain and liver of a rat model for chronic Sake (Japanese alcoholic beverage) intake. *Electrophoresis*. 2009; 30:1259–1275. [PubMed: 19382137]
- Matsuda-Matsumoto H, Iwazaki T, Kashem MA, Harper C, Matsumoto I. Differential protein expression profiles in the hippocampus of human alcoholics. *Neurochem Intl*. 2007; 51:370–376.
- Matsumoto I. Proteomics approach in the study of the pathophysiology of alcohol-related brain damage. *Alcohol Alcohol*. 2009; 44:171–176. [PubMed: 19136498]
- Mayfield RD, Lewohl JM, Dodd PR, Herlihy A, Liu J, Harris RA. Patterns of gene expression are altered in the frontal and motor cortices of human alcoholics. *J Neurochem*. 2002; 81:802–813. [PubMed: 12065639]
- McBride WJ, Schultz JA, Kimpel MW, McClintick JN, Wang M, You J, Rodd ZA. Differential effects of ethanol in the nucleus accumbens shell of alcohol-preferring (P), alcohol-non-preferring (NP) and Wistar rats: a proteomics study. *Pharmacol Biochem Behav*. 2009; 92:304–313. [PubMed: 19166871]
- Nesvizhskii AI, Aebersold R. Analysis, statistical validation and dissemination of large-scale proteomics datasets generated by tandem MS. *Drug Discov Today*. 2004; 9:173–181. [PubMed: 14960397]
- Pentney RJ, Dlugos CA. Cerebellar Purkinje neurons with altered terminal dendritic segments are present in all lobules of the cerebellar vermis of ageing, ethanol-treated F344 rats. *Alcohol Alcohol*. 2000; 35:35–43. [PubMed: 10684774]

- Pfefferbaum A, Adalsteinsson E, Sullivan EV. Dysmorphology and microstructural degradation of the corpus callosum: Interaction of age and alcoholism. *Neurobio Aging*. 2006; 27:994–1009.
- Pfefferbaum A, Lim KO, Desmond JE, Sullivan EV. Thinning of the corpus callosum in older alcoholic men: A magnetic resonance imaging study. *Alcohol Clin Exp Res*. 1996; 20:752–757. [PubMed: 8800395]
- Pfefferbaum A, Rosenbloom M, Rohlfing T, Sullivan EV. Degradation of association and projection white matter systems in alcoholism detected with quantitative fiber tracking. *Bio Psych*. 2009; 65:680–690.
- Pfefferbaum A, Rosenbloom MJ, Serventi KL, Sullivan EV. Brain volumes, RBC status, and hepatic function in alcoholics after 1 and 4 weeks of sobriety: predictors of outcome. *Am J Psychiatry*. 2004; 161:1190–1196. [PubMed: 15229050]
- Pfefferbaum A, Zahr NM, Mayer D, Vinco S, Orduna J, Rohlfing T, Sullivan EV. Ventricular expansion in wild-type Wistar rats after alcohol exposure by vapor chamber. *Alcohol Clinical Exp Res*. 2008; 32:1459–1467. [PubMed: 18798357]
- Pitkin SR, Savage LM. Aging potentiates the acute and chronic neurological symptoms of pyridoxamine-induced thiamine deficiency in the rodent. *Beh Brain Res*. 2001; 119:167–177.
- Roberts AJ, Heyser CJ, Cole M, Griffin P, Koob GF. Excessive ethanol drinking following a history of dependence: animal model of allostasis. *Neuropsychopharmacology*. 2000; 22:581–594. [PubMed: 10788758]
- Sullivan EV, Harding AJ, Pentney R, Dlugos C, Martin PR, Parks MH, Desmond JE, Chen SH, Pryor MR, De Rosa E, Pfefferbaum A. Disruption of frontocerebellar circuitry and function in alcoholism. *Alcohol Clinical Exp Res*. 2003; 27:301–309. [PubMed: 12605080]
- Sullivan EV, Rohlfing T, Pfefferbaum A. Pontocerebellar volume deficits and ataxia in alcoholic men and women: no evidence for “telescoping”. *Psychopharmacology*. 2010; 208:279–290. [PubMed: 19943036]
- Tabakoff B. Neurotransmitter function and alcoholism. *Alcohol Clinical Exp Res*. 1979; 3:351–352. [PubMed: 42319]
- Taniguchi K, Nonami T, Nakao A, Harada A, Kurokawa T, Sugiyama S, Fujitsuka N, Shimomura Y, Hutson SM, Harris RA, Takagi H. The valine catabolic pathway in human liver: effect of cirrhosis on enzyme activities. *Hepatology*. 1996; 24:1395–1398. [PubMed: 8938168]
- Tarnowska-Dziduszko E, Bertrand E, Szpak G. Morphological changes in the corpus callosum in chronic alcoholism. *Folia Neuropathol*. 1995; 33:25–29. [PubMed: 8673416]
- Volkow ND, Hitzemann R, Wolf AP, Logan J, Fowler JS, Christman D, Dewey SL, Schlyer D, Burr G, Vitkun S, et al. Acute effects of ethanol on regional brain glucose metabolism and transport. *Psych Res*. 1990; 35:39–48.
- Witzmann, FA. Preparation of Mammalian Tissue Samples for Two-dimensional Electrophoresis. In: Walker, JM., editor. *The Proteomics Protocols Handbook*. Totowa: The Humana Press; 2005. p. 31–35.
- Witzmann FA, Li J, Strother WN, McBride WJ, Hunter L, Crabb DW, Lumeng L, Li TK. Innate differences in protein expression in the nucleus accumbens and hippocampus of inbred alcohol-preferring and -nonpreferring rats. *Proteomics*. 2003; 3:1335–1344. [PubMed: 12872235]
- Zahr, NM.; Gu, M.; Mayer, D.; Spielman, D.; Sullivan, EV.; Pfefferbaum, A. Glutamate and Glutamine Changes Induced by Ethanol Treatment in the Rat Brain Detectable with CT-PRESS at 3T. *International Society for Magnetic Resonance Imaging*; Stockholm, Sweden: 2010a.
- Zahr NM, Mayer D, Rohlfing T, Hasak M, Hsu O, Vinco S, Orduna J, Luong R, Sullivan EV, Pfefferbaum A. Brain Injury and Recovery Following Binge Ethanol: Evidence from In Vivo Magnetic Resonance Spectroscopy. *Biol Psych*. 2010b; 67:846–854.
- Zahr NM, Mayer D, Vinco S, Orduna J, Luong R, Sullivan EV, Pfefferbaum A. In vivo evidence for alcohol-induced neurochemical changes in rat brain without protracted withdrawal, pronounced thiamine deficiency, or severe liver damage. *Neuropsychopharmacology*. 2009; 34:1427–1442. [PubMed: 18704091]
- Zahr NM, Pitel AL, Chanraud S, Sullivan EV. Contributions of Studies on Alcohol Use Disorders to Understanding Cerebellar Function. *Neuropsychology Review*. 2010c in press.

Zeisel SH. Choline phospholipids: signal transduction and carcinogenesis. *FASEB J.* 1993; 7:551–557.
[PubMed: 8472893]

Figure 1.

Demonstrates the location and size of micropunches from the 6 regions evaluated. Ten punches were taken from the PFC (blue) in the ventral medial cortical structures anterior to the corpus callosum, 10 punches from the most anterior and dorsal portions of the STR (green), 38 punches for CC genu and body (red) starting far anterior and ending at the hippocampus, 10 punches in the most anterior superior portions of the AV (purple), and 10 punches for the ADLC (orange), starting slightly posterior and lateral to the AV.

Table 1

	Identified Protein	P-value	Q-value	Fold Change					
				STR	PFC	CCg	CCb	AV	ADLC
STR	Akr1c6	0.00001	0.312	-1.4	1.0	-1.2	-1.2	1.0	-1.3
	Idh3b	0.0019	0.435	1.3	1.0	1.0	1.0	1.0	-1.3
	Crym	0.0119	0.435	-1.3	-1.2	-1.1	-1.1	-1.2	-1.2
	Uchl1	0.0027	0.435	-1.2	1.0	1.0	1.0	1.0	1.2
	Aip	0.0122	0.435	-1.2	-1.1	1.0	1.0	1.1	1.1
PFC	Stmn1	0.0056	0.435	-1.2	1.1	-1.1	-1.1	1.0	-1.1
	Ldhh	0.0122	0.435	-1.1	1.0	-1.1	-1.1	1.1	1.0
	Tpm2	0.0105	0.414	1.1	1.6	1.4	1.3	1.0	1.2
	Gsto1	0.0090	0.414	1.2	1.4	1.0	1.0	1.0	-1.3
	Myc12b	0.0026	0.414	1.0	1.3	1.0	-1.1	1.0	1.0
	Syn2	0.0048	0.414	1.1	1.2	1.1	1.0	1.0	1.2
	Tkt	0.0138	0.414	1.1	-1.2	1.0	-1.1	1.1	1.1
	Hibch	0.0066	0.414	-1.2	-1.2	1.1	-1.2	1.1	1.1
	Cacybp	0.0068	0.414	1.0	-1.2	-1.1	1.0	-1.1	-1.1
	Itpa	0.0040	0.414	1.0	1.2	1.0	-1.1	1.1	-1.1
CCg	Cox6a1	0.0088	0.414	1.0	1.2	1.0	1.0	1.1	1.0
	Gnb2l1	0.0050	0.414	-1.1	-1.2	-1.1	-1.2	1.0	-1.1
	Hspd1	0.0025	0.414	1.3	1.2	1.1	1.0	1.1	1.1
	Qdpr	0.0011	0.414	1.0	-1.1	1.0	1.0	-1.1	1.0
	Vdac2	0.0123	0.414	1.0	-1.1	1.1	1.0	1.0	1.1
CCb	Adk	0.0143	0.519	-1.1	1.0	-1.2	-1.2	1.0	1.0
	Pkm2	0.0141	0.519	-1.1	1.0	-1.2	-1.2	-1.1	1.1
	Eif5a	0.0030	0.447	1.0	1.0	1.0	-1.4	1.0	-1.1
	Tuba1	0.0010	0.447	1.0	1.0	1.0	-1.3	-1.1	-1.1
	Fabp7	0.0098	0.447	-1.2	-1.1	-1.1	-1.2	1.0	-1.1
	Pdia3	0.0133	0.447	-1.2	1.0	-1.1	-1.2	1.0	1.1
	Tuba1	0.0088	0.447	1.0	1.1	1.0	-1.2	1.0	-1.1

	Identified Protein	P-value	Q-value	Fold Change					
				STR	PFC	CCg	CCb	AV	ADLC
	Arhgdia	0.0072	0.447	1.0	1.0	-1.1	-1.2	1.1	1.0
	Nefl	0.0143	0.447	1.0	1.1	1.1	1.2	-1.3	1.1
AV	Hbb	0.0151	0.507	1.0	1.2	1.0	-1.1	-1.4	-1.1
	Snap25	0.0147	0.507	1.0	1.0	-1.1	-1.1	-1.3	-1.3
	Snap25	0.0095	0.507	1.0	1.0	-1.2	-1.1	-1.2	-1.2
	Hspa5	0.0022	0.507	1.3	1.0	1.1	1.3	1.2	1.2
	Tufm	0.0047	0.507	1.0	1.0	1.1	1.2	1.2	1.1
	Hsd17b10	0.0022	0.507	1.1	1.0	1.2	1.0	1.2	1.0
	Actb	0.0118	0.507	1.0	1.0	1.0	1.0	1.1	1.0
	Acta1	0.0141	0.394	-1.1	-1.1	-1.2	-1.2	-1.1	-1.3
ADLC	Ptdx5	0.0130	0.394	1.0	1.0	1.2	1.0	1.0	1.3
	Hist1h4b	0.0131	0.394	1.3	1.2	1.0	-1.3	1.0	-1.3
	Nme1	0.0105	0.394	1.0	1.1	1.1	1.0	1.0	1.3
	Phox2a	0.0142	0.394	1.0	1.0	1.0	1.3	1.0	1.2

Table 2

Alphabetic listing of identified proteins that were changed, their relative abundance as a percent of control levels, the brain region which displayed this significant ($P < 0.05$) difference, and a general description of their function

Gene ID	% of Control	Protein ID	Description
Acta1	76% in ADLC	actin α 1	a cytoskeletal protein; major constituent of the contractile apparatus of skeletal muscle; missense mutations of the Acta1 gene reported to be associated with brain deformities and cognitive impairment (Goez et al., 2005).
Actb	107% in AV	actin β	a cytoskeletal protein involved in cell motility, structure, and integrity.
Adk	86% in CCg	adenosine kinase	catalyzes the transfer of the γ -phosphate from ATP to adenosine, thereby regulating concentrations of both extracellular adenosine and intracellular adenine nucleotides.
Aip	82% in STR	aryl-hydrocarbon receptor-interacting protein	a ligand-activated transcription factor/receptor for aryl hydrocarbons; it regulates the expression of xenobiotic metabolizing enzymes and inhibits the activity of cyclic AMP phosphodiesterase; it may regulate survivin stability (Kang and Altieri, 2006) implicating a role in combating apoptosis.
Akr1c6	73% in STR	aldo-keto reductase family 1, member C6	active toward androgens, estrogens, and xenobiotics catalyzing the conversion of aldehydes and ketones to their corresponding alcohols using NADH or NADPH as cofactors.
Arhgdia	86% in CCB	rho GDP dissociation inhibitor (GDI) alpha	aplysia Ras-related homologs, also called Rho genes may be kept in the inactive, guanosine diphosphate (GDP)-bound state by interaction with GDP dissociation inhibitors such as Arhgdia.
Cacybp	84% in PFC	calcyclin binding protein	involved in calcium-dependent ubiquitination and subsequent proteosomal degradation; frequently colocalized with tau and tubulin suggesting a role in cytoskeletal physiology (Filipek et al., 2008).
Cox6a1	117% in PFC	cytochrome C oxidase polypeptide VIa-liver(mitochondrial precursor)	the terminal enzyme of the mitochondrial respiratory chain; catalyzes the electron transfer from reduced cytochrome C to oxygen; implicated in controlling apoptosis via BAK (Eun et al., 2008).
Crym	79% in STR	mu-crystallin homolog	possesses catalytic and deaminase activity; implicated in the regulation of intracellular concentrations of thyroid hormone.
Eif5a	73% in CCB	eukaryotic translation initiation factor 5A-1	an mRNA-binding protein important for translation elongation and mRNA turnover; involved in actin dynamics, cell-cycle progression, stress responses, maintenance of cell-wall integrity (Chatterjee et al., 2006); can regulate apoptosis via interactions with p53 and TNF- α (Rahman-Roblick et al., 2007).
Fabp7	82% in CCB	fatty acid binding protein, brain	binds long-chain fatty acids and other hydrophobic ligands regulating their uptake, transport, and metabolism.
Gnb211	86% in PFC	G-protein, subunit β -2-like-1	implicated in intracellular binding of protein kinase C; via its association with SRC may be involved in PI3K and MAPK signaling pathways involved in cell proliferation, migration, and survival (Cozzoli et al., 2009; Roberto et al., 2003).
Gsto	144% in PFC	glutathione S-transferase Ω 1	acts as a small stress response protein, a glutathione-dependent dehydroascorbate reductase, and is implicated in cellular redox homeostasis.
Hbb	73% in AV	hemoglobin subunit β -1	the β -globin chain of hemoglobin, which binds and transports oxygen to tissue.

Gene ID	% of Control	Protein ID	Description
Hibch	82% in PFC	3-hydroxyisobutyryl-coenzyme A hydrolase (isoform 2)	participates in 3 metabolic pathways: valine, leucine and isoleucine degradation; beta-alanine metabolism; and propanoate metabolism.
Hist1h4b	78% in ADLC	histone cluster 1, H4b (isoform)	histones interact with linker DNA between nucleosomes and function in the compaction of chromatin into higher order structures and thereby play an important role in transcription regulation, DNA repair, DNA replication, and chromosomal stability.
Hsd17b10	116% in AV	17- β -hydroxysteroid dehydrogenase 10	also known as 3-hydroxyacyl-CoA dehydrogenase type II; a member of the short-chain dehydrogenase/reductase superfamily that catalyze the oxidation of a wide variety of fatty acids, alcohols, and steroids.
Hspa5	121% in AV	heat shock protein 5 (glucose-regulated protein, 78kDa)	a member of the chaperonin family of proteins whose expression increases under stress; prevents misfolding and promotes refolding and proper assembly of unfolded polypeptides generated under stress conditions;
Hspd1	115% in PFC	heat shock protein 1 (mitochondrial, 10 kDa)	a member of the chaperonin family of proteins whose expression increases under stress; prevents misfolding and promotes refolding and proper assembly of unfolded polypeptides generated under stress conditions; may also function as a signaling molecule in the cellular immune response.
Idh3b	127% in STR	isocitrate dehydrogenase [NAD ⁺] subunit β	catalyzes the oxidative decarboxylation of isocitrate to 2-oxoglutarate
Itpa	118% in PFC	inosine triphosphatase	a metabolic protein that hydrolyzes inosine triphosphate and deoxyinosine triphosphate to the monophosphate and diphosphate nucleotides.
Ldhb	91% in STR	L-lactate dehydrogenase B chain	functions in the glycolytic pathway catalyzing the interconversion of lactate and pyruvate; implicated in the expression of cell surface antigens during T cell development (Fujishiro et al., 2000).
Mylc2b	128% in PFC	myosin regulatory light chain 2-B (smooth muscle isoform)	a cytoskeletal protein implicated in cell locomotion and cytokinesis.
Nefl	116% in CCB	neurofilament light polypeptide	a constituent of the axoskeleton; helps functionally maintain neuronal caliber; implicated in intracellular transport to axons and dendrites.
Nme1	126% in ADLC	nucleoside diphosphate kinase A	implicated in the synthesis of nucleoside triphosphates other than ATP; involved in cell proliferation, differentiation, and development, signal transduction, G protein-coupled receptor endocytosis, and gene expression.
Pdia3	83% in CCB	protein disulfide isomerase A3 precursor	interacts with calreticulin and calnexin to modulate folding of newly synthesized glycoproteins; plays a cytoprotective role against oxidative stress; functions in antigen presentation and T cell responses (Garbi et al., 2006).
Phox2a	122% in ADLC	paired homeobox protein 2A	a transcription factor that regulates the expression of tyrosine hydroxylase and dopamine beta-hydroxylase, two catecholaminergic biosynthetic enzymes essential for the differentiation and maintenance of the central noradrenergic system.
Pkm2	84% in CCG	pyruvate kinase isozymes M1/M2 (isoform M1)	a glycolytic enzyme that catalyzes the transfer of a phosphoryl group from phosphoenolpyruvate to ADP generating pyruvate and ATP; interacts with thyroid hormone mediating its metabolic effects (Sabell et al., 1985).
Prdx5	128% in ADLC	peroxiredoxin 5 (isoform)	an antioxidant enzyme that reduces hydrogen peroxide and alkyl hydroperoxides and thus implicated in antioxidant neuroprotection.
Qdpr	87% in PFC	dihydropteridine reductase	catalyzes the NADH-mediated reduction of quinonoid dihydrobiopterin to tetrahydrobiopterin, which is an essential cofactor for phenylalanine, tyrosine, and

Gene ID	% of Control	Protein ID	Description
			tryptophan hydroxylases, enzymes necessary for the production of the neurotransmitters dopamine and serotonin.
Snap25	77% in AV	synaptosomal-associated protein, 25kDa, isoform 25b (charge variant)	a presynaptic plasma membrane protein associated with scaffolding proteins involved in vesicle docking and membrane fusion, thus regulating neurotransmitter release; implicated in axonal growth.
Snap25	80% in AV	synaptosomal-associated protein, 25kDa, isoform 25b (charge variant)	a presynaptic plasma membrane protein associated with scaffolding proteins involved in vesicle docking and membrane fusion, thus regulating neurotransmitter release; implicated in axonal growth.
Stmn1	83% in STR	stathmin	a ubiquitous cytosolic phosphoprotein implicated in integrating regulatory signals of the cellular environment; involved in regulating the microtubule filament system; STMN1 knock-out mice are deficient in innate and learned fear (Martel et al., 2008).
Syn2	123% in PFC	synapsin 2 (isoform IIa)	a neuron-specific phosphoprotein involved in vesicle trafficking to synapses, the regulation of neurotransmitter release, and synaptic morphology.
Tkt	81% in PFC	transketolase	connects the pentose phosphate pathway to glycolysis, feeding excess sugar phosphates into the main carbohydrate metabolic pathway.
Tpm2	156% in PFC	tropomyosin β chain (isoform 2)	a cytoskeletal protein that regulates actin binding and ATPase activity.
Tuba1 α	77% in CCB	tubulin α 1A chain (charge variant)	a cytoskeletal protein that forms heterodimers with β -tubulin; acts as a structural component of the microtubule cytoskeleton; plays a role in microtubule-based processes; colocalized with Cacybp.
Tuba1 α	83% in CCB	tubulin α 1A chain (charge variant)	a cytoskeletal protein that forms heterodimers with β -tubulin; acts as a structural component of the microtubule cytoskeleton; plays a role in microtubule-based processes; colocalized with Cacybp.
Tufm	118% in AV	tu translation elongation factor	participates in protein translation/synthesis.
Uchl1	80% in STR	ubiquitin carboxyl-terminal hydrolase isozyme L1	involved in the processing of ubiquitinated proteins; implicated in axonogenesis (Saigoh et al., 1999).
Vdac2	91% in PFC	voltage-dependent anion-selective channel 2	implicated in Ca^{2+} homeostasis and ATP production/availability; interacts with the GABA-A benzodiazepine complex (Mehta and Ticku, 1999); can bind neurosteroids, and implicated in controlling apoptosis via BAK (Cheng et al., 2003).

ADLC = Anterior Dorsal Lateral Cerebellum; AV = Anterior Vermis; CCB = Corpus Callosum Body; CCG = Corpus Callosum Genu; STR = Dorsal Striatum; PFC = Prefrontal Cortex;

Table 3

Listing of identified proteins by region and function

	Neurotransmission	Metabolism	Cytoskeleton	Stress Response	Transcription/Translation
PFC	Syn2	Cox6a1	Mycl2b	Gsto	
	Gnb2l1	Itpa	Tpm2	Hspd1	
	Vdac2	Hibch	Cacybp		
	Qdpr	Tkt			
STR		Idh3b			Aip
		Akr1c6			
		Crym			
		Ldhb			
		Stmn1			
		Uchl1			
CCg		Adk			
		Pkm2			
CCb	Arhgdia	Fabp7	Nefl		Elf5a
		Pdia3	Tuba1g		
AV	Snap25	Hsd17b10	Actb	Hspa5	Tufm
		Hbb			
ADLC	Nme1		Acta1	Prdx5	Phox2a
					Hist1h4b

Table 4

Alphabetic listing of gene ID's for identified proteins that were changed in the present study and previous reports implicating its, or an isoform's role in alcoholism

Gene ID	Rodent Studies	Human Studies
Acta1	Δ gene expression ^{5,19,27} Δ protein expression ^{4,26,41}	Δ gene expression ¹² Δ protein expression ^{2,3,9,16,21}
Actb	Δ gene expression ^{5,19,27} Δ protein expression ^{4,26,41}	Δ gene expression ¹² Δ protein expression ^{2,3,9,16,21}
Adk		
Aip	Δ gene expression ²⁷ Δ protein expression ²³	
Akr1c6	Δ gene expression ⁶	Δ gene expression ¹⁵
Arhgdia		Δ gene expression ^{12,38}
Cacybp	Δ gene expression ⁵	
Crym		Δ gene expression ²⁵ Δ protein expression ^{2,17}
Cox6a1	Δ gene expression ^{7,27,28,30,32} Δ protein expression ²⁶	Δ gene expression ³³
Eif5a	Δ gene expression ^{13,28,30}	Δ gene expression ²⁹
Fabp7	Δ gene expression ³⁹ Δ protein expression ¹¹	Δ gene expression ²⁹ Δ protein expression ²¹
Gnb2l1	Δ gene expression ^{28,32,36,40} Δ protein expression ²⁶	Δ gene expression ²⁰
Gsto	Δ gene expression ^{13,19,31} Δ protein expression ²⁶	Δ gene expression ¹⁵ Δ protein expression ¹⁷
Hbb	Δ gene expression ¹⁹	
Hibch		
Hist1h4b	Δ gene expression ³⁰ Δ protein expression ²⁶	Δ gene expression ^{15,20}
Hsd17b10	Δ gene expression ³⁰	
Hspd1	Δ gene expression ⁷ Δ protein expression ^{4,26,41}	Δ gene expression ²⁰ Δ protein expression ^{2,9,17,21}
Hspa5	Δ gene expression ⁷ Δ protein expression ^{4,26,41}	Δ gene expression ²⁰ Δ protein expression ^{2,9,17,21}
Idh3b	Δ gene expression ³²	Δ gene expression ¹² Δ protein expression ^{16,17}
Itpa		

Gene ID	Rodent Studies	Human Studies
Ldhd	Δ gene expression ³⁵ Δ protein expression ^{26,41}	Δ protein expression ^{3,9,17}
Mylc2b		Δ gene expression ³³
Nefl	Δ gene expression ²⁷ Δ protein expression ²⁶	Δ gene expression ³⁸ Δ protein expression ^{2,16,17}
Nme1	Δ gene expression ⁵ Δ protein expression ²⁶	Δ gene expression ¹²
Pdia3	Δ gene expression ⁶	Δ gene expression ³³ Δ protein expression ^{3,17}
Phox2a		
Pkm2		
	Δ protein expression ²⁶	Δ protein expression ^{2,3,21}
Prdx5	Δ gene expression ²⁷ Δ protein	Δ protein expression ^{3,16,21}
Qdpr	Δ gene expression ^{8,19,37}	Δ protein expression ³
Snap25	Δ gene expression ¹⁹ Δ protein expression ^{4,26}	Δ protein expression ^{2,17}
Stmn1	Δ gene expression ³⁴	Δ protein expression ¹⁶
Syn2	Δ gene expression ^{8,19,27} Δ protein expression ¹¹	Δ gene expression ²⁵
Tkt	Δ gene expression ^{19,34}	Δ gene expression ²² Δ protein expression ^{1,2,3}
Tpm2	Δ gene expression ^{6,13,30,40} Δ protein expression ⁴	Δ protein expression ^{16,17,21}
Tuba1a	Δ gene expression ^{19,37,40} Δ protein expression ²⁶	Δ gene expression ¹⁰ Δ protein expression ^{16,17,21}
Tufm	Δ protein expression ²⁶	Δ protein expression ^{2,3}
Uchl1	Δ gene expression ^{27,42} Δ protein expression ¹¹	Δ protein expression ^{1,21,24}
Vdac2	Δ protein expression ^{4,26}	Δ protein expression ^{2,21}

¹ Alexander-Kaufman et al., 2006;

² Alexander-Kaufman et al., 2007a;

- ³ Alexander-Kaufman et al., 2007b;
- ⁴ Bell et al., 2006;
- ⁵ Bell et al., 2009; Carr et al., 2007;
- ⁷ Ciccocioppo et al., 2006;
- ⁸ Edenberg et al., 2005;
- ⁹ Etheridge et al., 2009;
- ¹⁰ Flatscher-Bader et al., 2005;
- ¹¹ Hargreaves et al., 2009;
- ¹² Hill et al., 2004;
- ¹³ Hitzemann et al., 2004;
- ¹⁴ Hoffman & Tabakoff, 2005;
- ¹⁵ Iwamoto et al., 2004;
- ¹⁶ Kashem et al., 2007;
- ¹⁷ Kashem et al., 2008;
- ¹⁸ Kerns et al., 2005;
- ¹⁹ Kimpel et al., 2007;
- ²⁰ Lewohl et al., 2000;
- ²¹ Lewohl et al., 2004;
- ²² Liu et al., 2006;
- ²³ Masuo et al., 2009;
- ²⁴ Matsuda-Matsumoto et al., 2007;
- ²⁵ Mayfield et al., 2002;
- ²⁶ McBride et al., 2009;
- ²⁷ McBride et al., 2010;
- ²⁸ Mulligan et al., 2006;
- ²⁹ Prescott et al., 2006;
- ³⁰ Rodd et al., 2008;
- ³¹ Saba et al., 2006;
- ³² Saito et al., 2004;
- ³³ Sokolov et al., 2003;
- ³⁴ Sommer et al., 2006;
- ³⁵ Tabakoff et al., 2003;
- ³⁶ Tabakoff et al., 2008;

³⁷Tabakoff et al., 2009;

³⁸Thibault et al., 2000;

³⁹Treadwell & Singh, 2004;

⁴⁰Wang et al., 2007;

⁴¹Witzemann et al., 2003;

⁴²Xu et al., 2001.